Cancer: Page 2

Study: AI assists discovery of prostate cancer subtypes
By Matt Limb
Prostate tumors have been found to evolve along multiple pathways, leading to two distinct disease types with “pivotal” implications for diagnosis and treatment, say scientists.
March 8, 2024
3 D Prostate Cancer Viral Social
MD Anderson Cancer Center acquires cell therapy switch technologies
By Matt Limb
The University of Texas MD Anderson Cancer Center has acquired inducible switch technologies for development in cell therapy programs from Bellicum Pharmaceuticals.
March 7, 2024
Cell Analysis Therapy Engineering Social
MD Anderson Cancer Center, C-Biomex collaborate on CA9-targeting radioligand
By Matt Limb
The University of Texas MD Anderson Cancer Center has signed an agreement with South Korean company C-Biomex to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.
February 29, 2024
Cancer Cell Target2 Social
Reversible, multiplex CRISPR system enhances efficacy of CAR-T cell therapy
By Nick Paul Taylor
A CRISPR system that uses Cas13d to make reversible changes to the expression of multiple genes could overcome limitations that are holding back CAR-T cell therapies, a paper published in Cell suggests.
February 28, 2024
Licensed under Creative Commons
Bavarian Nordic ends cancer vaccine program
By LabPulse.com staff writers
Biotech firm Bavarian Nordic is ceasing all work on its cancer vaccine program, instead prioritizing its infectious disease projects.
February 22, 2024
Vial Vaccine Vial Tech Social
National Cancer Institute launches network to evaluate cancer screening technologies
By LabPulse.com staff writers
In support of the Biden-Harris administration’s Cancer Moonshot initiative, the U.S. National Institutes of Health has launched the Cancer Screening Research Network, a clinical trial network for evaluating emerging cancer screening technologies.
February 22, 2024
Cancer Therapy Targeted Social
FDA grants accelerated approval to Iovance’s melanoma cell therapy
By LabPulse.com staff writers
The FDA granted accelerated approval to Iovance Biotherapeutics’ T-cell therapy treatment for unresectable or metastatic melanoma.
February 21, 2024
Melanoma Social
Freenome raises $254M in funding to advance cancer test pipeline
By LabPulse.com staff writers
Biotech firm Freenome has raised $254 million in new funding from new and existing investors to accelerate its pipeline of early detection cancer tests for its multiomics platform.
February 15, 2024
Research Money Social
Gold-enhanced nanopore sensors detect ovarian cancer biomarker in urine
By Nick Paul Taylor
Nanopore sensors that use gold nanoparticles to capture certain peptides could enable the detection of ovarian cancer biomarkers in urine samples, according to a paper published in ACS Sensors.
February 14, 2024
Ovarian Cancer2 Social
High hopes for accurate blood test detecting malignant brain tumors
By Matt Limb
A simple blood test to detect malignant brain tumors that can be hard to locate could spare many cancer patients risky and invasive surgery, say scientists.
February 9, 2024
Blood Test Samples Lab Social
U.K. trial for mRNA-based cancer therapy begins
By Matt Limb
Cancer patients in the U.K. are receiving an experimental mRNA therapy designed to help their bodies recognize and fight cancer cells.
February 7, 2024
Messenger Rna M Rna Social
NHS launches Jewish BRCA mutations testing program
By LabPulse.com staff writers
The U.K. National Health Service (NHS) is launching a national genetic testing program aimed at people in England with Jewish ancestry who may be carriers of mutations in BRCA1 and BRCA2 genes that increase their risk of certain cancers.
February 5, 2024
Dna Genome Gene Targeted Social
Previous Page
Page 2 of 96
Next Page